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Summary
Hepatic gluconeogenesis plays a key role in the main-
tenance of glucose homeostasis. The hormone glucagon
stimulates this process, whereas insulin and adiponectin
are inhibitory. In a recent report, Koo et al identify the
transcriptional regulator TORC2 (Transducer of Regu-
lated CREB activity 2) as a pivotal component of the
gluconeogenic program.(1) Both insulin and AMPK in-
crease the phosphorylation of TORC2, while glucagon
suppresses it. This in turn regulates the nuclear/cyto-
plasmic shuttling of TORC2and its ability to transactivate
gluconeogenic genes. Thus, TORC2 might serve as a
gluconeogenic ‘‘molecular switch’’ that senses hormones
and cellular energy status. BioEssays 28:231–234,
2006.  2006 Wiley Periodicals, Inc.
Introduction
The incidence of type 2 diabetes mellitus is reaching epidemic
proportions, becoming one of the major causes of morbidity
andmortality across the globe. Despite periods of feeding and
fasting, in normal individuals plasma glucose remains in a
narrow range. This tight control of glucose concentration is
determined bya balance between glucose absorption from the
intestine, production by the liver, and uptake in muscle and
fat.(2) Glucose production in the liver is controlled primarily by
gluconeogenesis.(3) The hormonal regulation of gluconeogen-
esis involves the transcriptional control of several key meta-
bolic enzymes, including phosphoenolpyruvate carboxykinase
(PEPCK) and glucose-6-phosphatase (G6Pase). In the fasted
state, glucagon is secreted, in turn increasing PEPCK and
G6Pase levels, and elevating hepatic glucose output. In
contrast, in the fed state, insulin inhibits the transcription of
these genes, thereby shutting down gluconeogenesis.
Gluconeogenesis and CREB
The transcription factor CREB (cAMP Responsive Element
Binding Protein) plays a critical role in the induction of
gluconeogenic genes.(4) Glucagon increases cAMP produc-
tion, stimulating the phosphorylation of CREB at Ser133 by
protein kinase A (PKA). This subsequently induces the
recruitment of transcriptional coactivators such as CREB-
binding protein (CBP). Insulin opposes these effects, in part by
increasing the phosphorylation of CBP at Ser436, thereby
disrupting the CREB–CBP complex.(5) The ability of CREB to
regulate gluconeogenesis is largely dependent on the
transcription factor PGC-1a.(6,7) PGC-1a is a transcriptional
target of CREB, and its expression is triggered by elevated
cAMP levels. PGC-1a can also transactivate the PEPCK gene
in response to glucocorticoids.
A recent search for additional coactivators of CREByielded
the family of TORC (transducer of regulated CREB activity)
proteins.(8,9) TORCs can potentiate the activity of both wild-
type and phosphorylation-defective mutants of CREB.
Although they interact with the DNA-binding/dimerization
domain of CREB, they do not affect the ability of CREB to
bind DNA. Instead, TORCs facilitate the ability of CREB to
recruit the basal transcription machinery.
TORCs: regulatory partners of
CREB in gluconeogenesis
Koo et al(1) have elucidated the critical role TORC2 plays in the
regulation of gluconeogenesis. Early studies paradoxically
showed that both insulin and glucagon increased the
phosphorylation of CREB at Ser133, suggesting that CREB
phosphorylation alone is unable to distinguish between fasting
and feeding signals. Nevertheless, insulin can also inhibit
CREB-mediated gluconeogenesis through the phosphoryla-
tion of CBP, resulting in the disruption of the CREB–CBP
complex. Koo et al examinedmice with a knock-inmutation for
CBP (CBPkix) deficient forCREBbinding.Despite the absence
of CREB–CBP complexes, CBPkix mice displayed normal
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blood glucose levels, and responded to fasting with normal
induction of gluconeogenic genes. Thus, the CREB–CBP
complex alone is insufficient for the activation of the gluco-
neogenic program.
They then turned to the TORC proteins as a possible
mechanism by which CREB mediates gluconeogenesis.
Expression of TORC2 in primary hepatocytes dramatically
increased the levels of PEPCK, G6Pase and PGC-1a in
response to elevated cAMP levels induced by forskolin. These
effects were abrogated by co-expression of a dominant
negative mutant of CREB, suggesting that the actions of
TORC2 critically depend on CREB. Infection of mice with
adenoviruses expressing TORC2 promoted fasting hypergly-
cemia. Conversely, infection with adenoviruses expressing
TORC2 RNAi produced hypoglycemic mice with reduced
expression of gluconeogenic genes during fasting. Thus
TORC2 likely plays an important role in maintaining glucose
metabolism through the control of hepatic gluconeogenesis.
Phosphorylation of TORC: a molecular
gluconeogenic switch
The identification of TORC2 as an important player in the
regulation of gluconeogenesis thus begs a key question, how
is this protein itself regulated? TORC2 can be phosphorylated
by the salt-inducible kinase 2 (SIK2) on Ser171, leading to its
associationwith 14-3-3 proteins and sequestration to the cyto-
plasm from the nucleus.(10,11) Moreover, cAMP inhibits SIK2
kinase activity through the PKA-dependent phosphorylation
on Ser587 of SIK2. Consequently, dephosphorylation of
TORC2 in response to cAMP results in nuclear translocation.
Koo et al explored in more detail how hormones might
impact the subcellular localization of TORC2 through phos-
phorylation. In mice treated with insulin, TORC2 undergoes
phosphorylation and is sequestered in the cytoplasm. Con-
versely, glucagon administration caused a dephosphorylation
of TORC2 and relocalization to the nucleus, permitting the
protein to now participate in transactivation of gluconeogenic
genes. Thus TORC2 is able to distinguish between fasting and
fed signals, and its phosphorylation may act as a molecular
switch to regulate gluconeogenesis.
Completing the regulatory circuit with SIK1
It has long been known that the stimulatory effect of cAMP on
PEPCK transcription is transient,(12) leading Koo et al. to
explore the temporal relationship of transcription to the
phosphorylation state of TORC2. Treatment with the protein
synthesis inhibitor cycloheximide abrogated Ser171 phos-
phorylation and increased themRNA levels of gluconeogeneic
genesandPGC-1asuggestinganegative regulatory feedback
loop that is dependent on de novo protein synthesis.
Unsurprisingly, SIK1 appears to be a key component of
this negative feedback loop. The levels of SIK1, but not SIK2
or SIK3, were upregulated in liver upon fasting. Primary
hepatocytes treated with forskolin responded similarly, and
expression of TORC2 further potentiated SIK1 induction.
Importantly, pretreatment with cycloheximide blocked the
increase in SIK1 levels, demonstrating that SIK1 is indeed
part of the inducible negative regulatory feedback loop on
gluconeogenesis. Analysis of the SIK1 promoter region
identified two cAMP response elements, and CREB constitu-
tively occupied the promoter region by chromatin immunopre-
cipitation assays. Expression of PKA stimulated SIK1
promoter activity, whereas a dominant negative mutant of
CREB blocked it. Treatment of cells with forskolin also
increased promoter occupancy by TORC2 and phospho-
CREB, further demonstrating the role of the TORC2–CREB
pathway in the SIK1-mediated negative feedback loop.
The essential role of SIK was demonstrated in primary
hepatocytes. SiRNA knockdown of SIK1 blocked glucagon-
stimulated TORC2 phosphorylation and further activated the
gluconeogenic program. Similarly, depletion of SIK1 in fasted
mice increased glucose levels and expression of gluconeo-
genic genes compared to controls, whereas infection of fasted
mice with adenoviruses expressing SIK1 lowered fasting
glucose levels and suppressed gluconeogenic gene expres-
sion. In primary hepatocytes, expression of SIK1 was able to
block wild-type TORC2 but not its S171Amutant in stimulating
PEPCK transcription. Taken together, these results demon-
strate that SIK1 inhibits gluconeogenesis through the phos-
phorylation of TORC2.
AMPK and TORC2
SIK1 belongs to the SNF1/AMPK family of protein kinases.(13)
After noticing that Ser171 of TORC2 falls within an AMPK
consensus substrate site, Koo et al demonstrated that it could
also be phosphorylated by AMPK, resulting in cytoplasmic
retention,while the localization of theS171Amutant of TORC2
wasunaffected.Moreover, theS171Amutant partially rescued
the AMPK-mediated suppression of PEPCK levels, suggest-
ing that TORC2 is a critical downstream target of AMPK in the
regulation of gluconeogenesis.
The hormones adiponectin and resistin reciprocally reg-
ulate gluconeogenesis by modulating the activation state of
AMPK.(14,15) It is likely that TORC2 is required for this effect.
Furthermore, the widely prescribed diabetes drug Metformin
has recently been shown to act through the LKB1–AMPK–
TORC2 pathway.(16) Thus, TORC2 may represent a central
switch to integrate signals from various hormones to regulate
gluconeogenesis.
Summary and future perspectives
The studies by Koo et al further clarify our understanding as to
how CREB and TORC2 operate to crank up the ‘‘gluconeo-
genic engine’’ (Fig. 1). During fasting, glucagon causes the
nuclear shuttling of TORC2 to allow association with and
coactivation of CREB on gluconeogenic genes. This involves
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the dephosphorylation of TORC2, likely through the PKA
catalyzed phosphorylation and inhibition of SIKs. Conversely,
insulin inhibits this process by inducing TORC2 phosphoryla-
tion through an unidentified mechanism. The ability of AMPK
to phosphorylate TORC2 further adds a level of control that
may bemodulated by cellular energy status or external stimuli
such as the hormones adiponectin and resistin. The identifica-
tion of TORC2 as a key player in CREB-mediated gluconeo-
genesis will likely yield new avenues for the design of
therapeutics in the treatment of diabetes.
The phosphorylation of TORC2 in response to insulin is
reminiscent of the way that the forkhead transcription factors,
FOXO1 and FOXA2, are regulated to suppress gluconeogen-
esis.(17,18) Insulin activates the kinase AKT to phosphorylate
these forkhead proteins, leading to their cytoplasmic retention
and/or degradation.(19–21) As of yet, the kinase that is respon-
sible for the phosphorylation of TORC2 by insulin remains
unknown. Is TORC2 a target of AKT? Are SIKs regulated by
insulin? These questions will likely be addressed soon.
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